Literature DB >> 10229222

Thalidomide on the comeback trail.

B F Hales.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229222     DOI: 10.1038/8371

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

1.  Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Authors:  J B Marriott; I A Clarke; K Dredge; G Muller; D Stirling; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 2.  Angiogenesis inhibitors in lung cancer.

Authors:  Edward S Kim; Roy S Herbst
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

Review 3.  Management of thalidomide toxicity.

Authors:  Irene M Ghobrial; S Vincent Rajkumar
Journal:  J Support Oncol       Date:  2003 Sep-Oct

4.  Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006.

Authors:  D P Cronin-Fenton; F Søndergaard; L A Pedersen; J P Fryzek; K Cetin; J Acquavella; J A Baron; H T Sørensen
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

5.  In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells.

Authors:  Min Li; Wan Sun; Ya-ping Yang; Bo Xu; Wen-yuan Yi; Yan-xia Ma; Zhong-jun Li; Jing-rong Cui
Journal:  Acta Pharmacol Sin       Date:  2008-12-22       Impact factor: 6.150

6.  Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.

Authors:  Hirotake Furihata; Satoshi Yamanaka; Toshiaki Honda; Yumiko Miyauchi; Atsuko Asano; Norio Shibata; Masaru Tanokura; Tatsuya Sawasaki; Takuya Miyakawa
Journal:  Nat Commun       Date:  2020-09-14       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.